Biotech entity
Every one of those 1 sits in a single category, funding. KRRO-110 is most often covered alongside Korro Bio, which appears in 1 of these 1 story. We currently track 1 Biotech story that mention KRRO-110, all published on March 9, 2026.
Last mentioned: Mar 9, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, funding. KRRO-110 is most often covered alongside Korro Bio, which appears in 1 of these 1 story. We currently track 1 Biotech story that mention KRRO-110, all published on March 9, 2026. Each carries 2 original sources on average.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 17 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering KRRO-110. Shared-story counts are live from our verified record — not editorial picks.
Korro Bio has announced an oversubscribed $85 million private placement to accelerate its proprietary RNA editing platform and clinical development. The funding provides a significant runway for the company's lead program, KRRO-110, targeting Alpha-1 Antitrypsin Deficiency.
KRRO-110 is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
